# 3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

> **NCT01374438** · PHASE2 · COMPLETED · sponsor: **Metabolic Solutions Development Company** · enrollment: 29 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** MSDC-0160
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01374438
- **Lead sponsor:** Metabolic Solutions Development Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-05
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01374438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01374438, "3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01374438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*